



## **BUYINS.NET Updates OxySure Therapeutics (OXYS) SqueezeTrigger Report**

- **Approximately 16.75 Million Shares Shorted Since June 2012**
- **Short Squeeze Expected When Stock Crosses Above \$0.47 SqueezeTrigger Price**

FRISCO, TX--(Marketwired - March 14, 2016) - OxySure Therapeutics, Inc. ([OXYS](#)) ("OxySure," or the "Company"), a global leader and medical device innovator of life-saving, easy-to-use emergency oxygen products with its "oxygen from powder" technology and other innovative emergency medical solutions today announced BUYINS.NET, <http://www.buyins.net>, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has updated coverage on OxySure Therapeutics (OTCQB: OXYS) after releasing the latest short sale data through March 11, 2016. The total aggregate number of shares shorted since June 2012 is approximately 16.75 million shares. Approximately 34.05% of daily trading volume is short selling. The SqueezeTrigger price for all OXYS shares shorted is \$0.47. A short squeeze is expected to begin when shares of OXYS close above the \$0.47 SqueezeTrigger price.

Click for original Report: <http://www.buyins.com/reports/oxys6-8-15.pdf>

Click for updated SqueezeTrigger: <http://www.buyins.com/images2/oxysstr3-13-16.jpg>

Click for updated Friction Factor: <http://www.buyins.com/images2/oxysff3-13-16.jpg>

Click here for detailed explanation: <http://www.buyins.com/brochure.pdf>

Friction Factor calculates if a fair market is being made in the shares of OXYS. 39% of the previous 38 trading days have been positive or bullish-biased and 61% have been negative or bearish-biased.

Regulation SHO requires bona-fide market-making activities to include making purchases and sales in roughly comparable amounts. The Commission has stated that bona-fide market-making DOES NOT include activity that is related to speculative selling strategies for investment purposes of the broker-dealer and is disproportionate to the usual market making patterns or practices of the broker-dealer in that security. Likewise, where a market-maker posts continually at or near the best offer, but does not also post at or near the best bid, the market-maker's activities would not generally qualify as bona-fide market-making. Moreover, a market-maker that continually executes short

sales away from its posted quotes would generally not be considered to be engaging in bona-fide market-making.

BUYINS.NET monitors OXYS market-makers daily for compliance with Fair Market-Making Requirements.

### **About BUYINS.NET**

BUYINS.NET, <http://www.buyins.net>, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies and comparable valuations.

### **About OxySure Therapeutics, Inc.**

OxySure Therapeutics, Inc. (OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. *In addition to oxygen products for public/lay responder usage, OxySure also markets emergency medical solutions including AEDs (Cardiac Science, Philips, Zoll, Physio Control, Defibtech, and HeartSine), Quickclot Bleeding Control solutions, resuscitation products and pulse oximetry products.* [www.OxySure.com](http://www.OxySure.com)

### **Contacts:**

Trevor Brucato  
RB Milestone Group, LLC.  
[tbrucato@rbmilestone.com](mailto:tbrucato@rbmilestone.com)  
+1 (212) 661-0075  
<http://www.rbmilestone.com/>

Thomas Ronk  
BUYINS.NET  
[tom@buyins.net](mailto:tom@buyins.net)  
800-715-9999  
<http://www.buyins.net>

## **Forward-Looking Statements**

*Statements in this earnings release that are not historical facts are considered to be forward-looking statements. Such statements include, but are not limited to, statements regarding management beliefs and expectations, based upon information available at the time the statements are made, regarding future plans, objectives and performance. All forward-looking statements are subject to risks and uncertainties, many of which are beyond management's control and actual results and performance may differ significantly from those contained in forward-looking statements. OxySure Therapeutics, Inc. intends any forward-looking statement to be covered by the Litigation Reform Act of 1995 and is including this statement for purposes of said safe harbor provisions. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. OxySure Therapeutics, Inc. undertakes no obligation to update any forward-looking statements to reflect events or circumstances that occur after the date as of which such statements are made. A discussion of certain risks and uncertainties that could cause actual results to differ materially from those contained in forward-looking statements is included in OxySure Therapeutics, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2014.*

### **DISCLAIMER:**

*BUYINS.NET is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. The Company has paid a non-affiliate \$1,117 per month for the first month of data provided in this report. OXYS has not approved the statements made in this release. Please read our report and visit our web site, <http://www.buyins.net>, for complete risks and disclosures.*